Rigel Pharmaceuticals, Incorporated

Pliant Therapeutics, Inc.

Cornell Research Foundation Inc.

Wisconsin Alumni Research Foundation

Rogel Pharmaceuticals, Inc.

Hui Li

Rajinder Paul Singh

Ankush Argade

Somasekhar Bhamidipati

Jeffrey Clough

Holger Keim

Vanessa Taylor

Catherine Sylvain

Donald G Payan

Kin Tso

Sacha Holland

David Carroll

Yan Chen

Alexander B Rossi

Susan Molineaux

Sambaiah Thota

Thilo J Heckrodt

Rose Yen

Darren J McMurtrie

Robin Cooper

Arvinder Sran

Esteban Masuda

Ryan Kelley

Pingyu Ding

Rao Kolluri

Brian Wong

Jack Maung

David John Morgans, Jr

Lan Jiang

Jing Zhang

Matthew Duncton

John Yudhistir Ramphal

Salvador Alvarez

Jacob Cha

Timothy Hom

Vadim Markovtsov

Gustave Bergnes

Randall Halcomb

John McLaughlin

Andy Atuegbu

Simon Shaw

Carlos A Valdez

Amit Lal

Marina Gelman

Susan Catalano

Sasha J Holland

Katerina Leftheris

Yajun Zheng

Chengguo Dong

Maureen Kay Reilly

Taisei Kinoshita

Haoran Zhao

Manuel Munoz

Tarikere Gururaja

Stephanie Yung

Chun Chen

Patrick Andre

Shihai Gu

Rongxian Ding

Mark Markovtsov

Shankar Radhakrishnan

Christopher Bailey

Douglass L Henderson

Emily Stauffer

Rajesh Duggirala

Hang Guo

Darren Finklestein

James P Blanchard

Avinder Sran

Someasekhar Bhamidipati

Vadim M V Markovtsov

The invention relates to compounds of formula (I): formula (I) or a salt thereof wherein R, R, R, R, X, m, n, p and q are as described herein. Compounds of formula (I) and pharmaceutical compositions thereof are αvβ6 integrin inhibitors that are useful for treating tissue specific fibrosis such as idiopathic pulmonary fibrosis (IPF) and nonspecific interstitial pneumonia (NSIP).

Amino acid compounds and methods of use

Disclosed embodiments concern interleukin receptor associated kinases (IRAK) inhibitors, such as oxazole compounds, and compositions comprising such inhibitors. Also disclosed are methods of making and using the compounds and compositions. The disclosed compounds and/or compositions may be used to treat or prevent an IRAK-associated disease or condition.

IRAK inhibitors and method for making and using

Disclosed embodiments concern novel interleukin receptor associated kinases (IRAK) inhibitors and compositions comprising such inhibitors. Also disclosed are methods of making and using the compounds and compositions. The disclosed compounds and/or compositions may be used to treat or prevent an IRAK-associated disease or condition.

Amide compounds and method for making and using

The invention encompasses compounds having formula I-V and the compositions and methods using these compounds in the treatment of conditions in which modulation of the JAK pathway or inhibition of JAK kinases, particularly JAK3, may be therapeutically useful.

Compositions and methods for inhibition of the JAK pathway

The invention relates to compounds of formula (I): or a salt thereof, wherein R, A, L, and Rand n are as described herein. Compounds of formula (I) and pharmaceutical compositions thereof are &#x3b1;v&#x3b2;1 integrin inhibitors that are useful for treating tissue specific fibrosis.

N-acyl amino acid compounds and methods of use

The invention encompasses compounds having formula I and the compositions and methods using these compounds in the treatment of conditions in which modulation of the JAK pathway or inhibition of JAK kinases, particularly JAK3, are therapeutically useful.

The invention relates to compounds of formula (I): or a salt thereof, wherein R, R, R, R, X, m, n, p and q are as described herein. Compounds of formula (I) and pharmaceutical compositions thereof are &#x3b1;v&#x3b2;6 integrin inhibitors that are useful for treating tissue specific fibrosis such as idiopathic pulmonary fibrosis (IPF) and nonspecific interstitial pneumonia (NSIP).

The invention relates to compounds of formula (A) and formula (I): or a salt thereof, wherein R, R, R, R, R, R, R, R, R, q and p are as described herein. Compounds of formula (A), formula (I), and pharmaceutical compositions thereof are &#x3b1;v&#x3b2;6 integrin inhibitors that are useful for treating fibrosis such as idiopathic pulmonary fibrosis (IPF) and nonspecific interstitial pneumonia (NSIP).

Pyrazole compounds and methods for making and using the compounds

The present invention provides methods of treating or preventing autoimmune diseases with 2,4-pyrimidinediamine compounds, as well as methods of treating, preventing or ameliorating symptoms associated with such diseases. Specific examples of autoimmune diseases that can be treated or prevented with the compounds include rheumatoid arthritis and/or its associated symptoms, systemic lupus erythematosis and/or its associated symptoms and multiple sclerosis and/or its associated symptoms.

Methods of treating or preventing autoimmune diseases with 2,4-pyrimidinediamine compounds

Disclosed are compounds of formula I, compositions containing them, and methods of use for the compounds and compositions in the treatment of conditions in which modulation of the JAK pathway or inhibition of JAK kinases, particularly JAK 2 and JAK3, are therapeutically useful. Also disclosed are methods of making the compounds.

The present invention provides 2,4-pyrimidinediamine compounds that inhibit the IgE and/or IgG receptor signaling cascades that lead to the release of chemical mediators, intermediates and methods of synthesizing the compounds and methods of using the compounds in a variety of contexts, including in the treatment and prevention of diseases characterized by, caused by or associated with the release of chemical mediators via degranulation and other processes effected by activation of the IgE and/or IgG receptor signaling cascades.

2,4-pyrimidinediamine compounds and their uses

Growing community of inventors

Santa Clara, CA, United States of America

Hui Li